Clause 5.2 follows the element requirement with the exchange requirement. It is concerned with the transmission of pharmaceutical product information between parties, and with the conditions that make the transmission usable. The document's scope already names the parties: a medicines regulator to another regulator, a company to a regulator, a trial sponsor to a regulator, a regulator to other stakeholders and to worldwide data sources. Clause 5.2 turns that list into an exchange requirement: the elements have to be carried in the structure the receiver expects, with the identifiers and the controlled vocabularies intact, and the receiver has to be able to acknowledge and validate what arrived. The clause sits beside the HL7 messaging references in clause 2 rather than replacing them. The specific message content and the acknowledgement rules are not in the public preview, so they are not stated in the text we hold.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.